Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival
Authors:
- Johannes F. FahrmannJFJohannes F. Fahrmann
- Dmitry GrapovDGDmitry Grapov
- Brett S. PhinneyBPBrett S. Phinney
- Carol StrobleCSCarol Stroble
- Brian C. DeFeliceBDBrian C. DeFelice
- William RomWRWilliam Rom
- David R. GandaraDGDavid R. Gandara
- Yanhong ZhangYZYanhong Zhang
- Oliver FiehnOliver Fiehn
- Harvey PassHPHarvey Pass
- Suzanne MiyamotoSMSuzanne Miyamoto
Open Access
- 27 October 2016
- journal article
- research article
- Published by Springer Nature in Clinical Proteomics
- Vol. 13 (1) , 1-12
Abstract
Lung cancer is the leading cause of cancer mortality in the United States. Non-small cell lung cancer accounts for 85% of all lung cancers for which adenocarcinoma is the most common histological type. Management of lung cancer is hindered by high false-positive rates due to difficulty resolving between benign and malignant tumors. Better molecular analysis comparing malignant and non-malignant tissues will provide important evidence of the underlying biology contributing to tumorigenesis. We utilized a proteomics approach to analyze 38 malignant and non-malignant paired tissue samples obtained from current or former smokers with early stage (Stage IA/IB) lung adenocarcinoma. Statistical mixed effects modeling and orthogonal partial least squares discriminant analysis were used to identify key cancer-associated perturbations in the adenocarcinoma proteome. Identified proteins were subsequently assessed against clinicopathological variables. Top cancer-associated protein alterations were characterized by: (1) elevations in APEX1, HYOU1 and PDIA4, indicative of increased DNA repair machinery and heightened anti-oxidant defense mechanisms; (2) increased LRPPRC, STOML2, COPG1 and EPRS, suggesting altered tumor metabolism and inflammation; (3) reductions in SPTB, SPTA1 and ANK1 implying dysregulation of membrane integrity; and (4) decreased SLCA41 suggesting altered pH regulation. Increased protein levels of HYOU1, EPRS and LASP1 in NSCLC adenocarcinoma was independently validated by tissue microarray immunohistochemistry. Immunohistochemistry for HYOU1 and EPRS indicated AUCs of 0.952 and 0.841, respectively, for classifying tissue as malignant. Increased LASP1 correlated with poor overall survival (HR 3.66 per unit increase; CI 1.37–9.78; p = 0.01). These results reveal distinct proteomic changes associated with early stage lung adenocarcinoma that may be useful prognostic indicators and therapeutic targets.Keywords
Funding Information
- LUNGevity and Thomas G. Labrecque Foundations award (201118739)
- National Institutes of Health (U24 DK097154)
- National Cancer Institute (EDRN 5U01CA111295-07)
This publication has 45 references indexed in Scilit:
- Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetaseNature Chemical Biology, 2012
- Knockdown of stomatin‐like protein 2 (STOML2) reduces the invasive ability of glioma cells through inhibition of the NF‐κB/MMP‐9 pathwayThe Journal of Pathology, 2011
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Membrane Domains Based on Ankyrin and Spectrin Associated with Cell-Cell InteractionsCold Spring Harbor Perspectives in Biology, 2009
- Review: Angiogenesis inhibitors in the treatment of non-small cell lung cancerTherapeutic Advances in Medical Oncology, 2009
- COPI Complex Is a Regulator of Lipid HomeostasisPLOS Biology, 2008
- Alteration of APE1/ref-1 expression in non-small cell lung cancer: The implications of impaired extracellular superoxide dismutase and catalase antioxidant systemsLung Cancer, 2008
- Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damageNucleic Acids Research, 2008
- Panel of Serum Biomarkers for the Diagnosis of Lung CancerJournal of Clinical Oncology, 2007
- Defects in energy homeostasis in Leigh syndrome French Canadian variant through PGC-1α/LRP130 complexGenes & Development, 2006